Status:
COMPLETED
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
Lead Sponsor:
Medivir
Conditions:
Herpes Labialis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and placebo for the treatment of recurrent herpes labialis.
Detailed Description
This was a randomized, double-blind, active- and vehicle-controlled study comparing the effects of ME-609, acyclovir in ME-609 vehicle, and vehicle alone. Treatment was subject-initiated within 1 hour...
Eligibility Criteria
Inclusion
- Generally good health
- History of recurrent herpes labialis with at last three episodes during the prior 12 months
Exclusion
- Treatment with antivirals or immunosuppressive agents within 2 weeks prior to randomization
- Pregnant and/or nursing women
- Continuous daily treatment with pain medication
- Significant skin condition that occur in the area of herpes recurrences
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
1443 Patients enrolled
Trial Details
Trial ID
NCT00361881
Start Date
July 1 2006
End Date
December 1 2007
Last Update
August 18 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Coastal Caroline Research Center
Mt. Pleasant, South Carolina, United States, 29464